Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0. It has been cited 64 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: CA214461, DE016572, AG069769 and P01 CA203628
National Institutes of Health
Grant: T32GM132055
NCI NIH HHS
Grant: R01 CA214461
NIDCR NIH HHS
Grant: R01 DE016572
NCI NIH HHS
Grant: P01 CA203628
NIGMS NIH HHS
Grant: R25 GM113278
NIA NIH HHS
Grant: R56 AG069769
National Institutes of Health
Grant: 1R01CA214461-01A1
Ceramide metabolism and the regulation of TGF-beta receptor signaling to control metastasis
National Institutes of Health
Grant: 5R01DE016572-13
Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and Therapy
National Institutes of Health
Grant: 1P01CA203628-01
Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling
National Institutes of Health
Grant: 5T32GM132055-05
Cellular, Biochemical and Molecular Sciences Training Program: Developing the skills and expertise needed for a changing biomedical landscape
National Institutes of Health
Grant: 1R56AG069769-01
Sphingolipid Metabolism and Signaling in the Regulation of Senescence and Aging
FWCI
4.39
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals